发明名称 |
TOXICITY MANAGEMENT FOR ANTI-TUMOR ACTIVITY OF CARS |
摘要 |
<p>The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.</p> |
申请公布号 |
EP2872171(A1) |
申请公布日期 |
2015.05.20 |
申请号 |
EP20130817210 |
申请日期 |
2013.07.12 |
申请人 |
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA;THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
发明人 |
JUNE, CARL, H.;LEVINE, BRUCE, L.;KALOS, MICHAEL D.;GRUPP, STEPHAN |
分类号 |
A61K39/00 |
主分类号 |
A61K39/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|